This site is intended for healthcare professionals

Novo Nordisk files for FDA approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes.

Read time: 1 mins
Last updated:21st Jan 2021
Published:21st Jan 2021
Condition: Diabetes Type 2
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest